Drug Profile
Research programme: integrin modulating recombinant protein therapeutics - Applied Integrin Sciences
Alternative Names: ADM-01; VicrostatinLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Applied Integrin Sciences
- Class Disintegrins; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Integrin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ovarian cancer; Solid tumours
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Ovarian cancer in USA (Parenteral)
- 28 Mar 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral, Controlled release)